NewAmsterdam Pharma COO Resigns; Enters Advisor Agreement

What Happened

• NewAmsterdam Pharma Co. N.V. announced that Douglas Kling resigned as Chief Operating Officer effective August 14, 2026 to become CEO of another clinical‑stage biotech company. On that date he signed a Separation Agreement with the company’s subsidiary NewAmsterdam Pharma Corporation and an Advisor Agreement with NewAmsterdam Pharma B.V. to provide transition and advisory services.
• Under the Advisor Agreement, Kling will be paid $50,000 per month plus reimbursable expenses. The advisory engagement is scheduled to terminate on May 14, 2027 unless ended earlier under the agreement’s terms.

Key Details

• Resignation effective date: August 14, 2026 (previously disclosed July 22, 2026).
• Advisor fee: $50,000 per month plus reimbursable expenses through May 14, 2027 (unless earlier terminated).
• Equity treatment: Unvested stock options and RSUs not vested as of Aug 14, 2026 are canceled and forfeited, except the portion eligible to vest solely for continued service through May 14, 2027 — those will continue to vest only if Kling provides services under the Advisor Agreement.
• Separation Agreement includes confidentiality, non‑disparagement, non‑solicitation covenants and a release of claims.

Why It Matters

• Leadership change: The COO role is a senior operational position; the departure and shift to a paid advisory role may affect near‑term operational continuity, especially during ongoing clinical programs such as the PREVAIL trial of obicetrapib.
• Compensation and incentives: Cancellation of most unvested equity reduces future equity dilution and removes long‑term incentive ties for the departing executive, while limited continued vesting ties compensation to advisory services through May 2027.
• Investors should note the company disclosed the agreements and material terms in the 8‑K; any additional details will be filed in the company’s next Form 10‑Q for the quarter ending Sept 30, 2026.